VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
This Quarter Return
+2.93%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$182M
AUM Growth
+$182M
(-5.1%)
Cap. Flow
-$9.35M
Cap. Flow
% of AUM
-5.14%
Top 10 Holdings %
Top 10 Hldgs %
6.2%
Holding
508
New
65
Increased
160
Reduced
215
Closed
68
Top Buys
| 1 |
Dow Inc
DOW
|
$1.16M |
| 2 |
Hershey
HSY
|
$1.04M |
| 3 |
Copart
CPRT
|
$1.03M |
| 4 |
lululemon athletica
LULU
|
$1.02M |
| 5 |
Progressive
PGR
|
$999K |
Top Sells
| 1 |
Lennar Class A
LEN
|
$952K |
| 2 |
TJX Companies
TJX
|
$909K |
| 3 |
Ameriprise Financial
AMP
|
$902K |
| 4 |
Abbott
ABT
|
$892K |
| 5 |
Home Depot
HD
|
$885K |
Sector Composition
| 1 | Healthcare | 25.65% |
| 2 | Financials | 14.09% |
| 3 | Technology | 11.21% |
| 4 | Energy | 10.21% |
| 5 | Materials | 8.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
376
Dynavax Technologies
DVAX
$1.16B
| $85.9K | 0.05% |
8,756
-3,371
| -28% | -$33.1K |
|
|
DICE
377
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $85.4K | 0.05% |
2,980
-1,147
| -28% | -$32.9K |
|
378
Dyne Therapeutics
DYN
$1.92B
| $84.5K | 0.05% |
7,335
-2,815
| -28% | -$32.4K |
|
379
Prothena Corp
PRTA
$445M
| $84.5K | 0.05% |
1,743
-673
| -28% | -$32.6K |
|
380
Edgewise Therapeutics
EWTX
$1.57B
| $83.4K | 0.05% |
12,507
-4,807
| -28% | -$32.1K |
|
381
Vaxcyte
PCVX
$4.1B
| $82.9K | 0.05% |
2,211
-853
| -28% | -$32K |
|
382
IDEAYA Biosciences
IDYA
$2.23B
| $82K | 0.05% |
5,972
-2,287
| -28% | -$31.4K |
|
383
Nuvalent
NUVL
$5.54B
| $81.6K | 0.04% |
3,127
-1,203
| -28% | -$31.4K |
|
384
Regenxbio
RGNX
$461M
| $80.5K | 0.04% |
4,257
-1,636
| -28% | -$30.9K |
|
|
EQRX
385
DELISTED
EQRx, Inc. Common Stock
EQRX
| $80.4K | 0.04% |
41,463
-15,942
| -28% | -$30.9K |
|
386
Nektar Therapeutics
NKTR
$553M
| $79K | 0.04% |
112,404
+1,984
| +2% | +$1.4K |
|
387
Arrowhead Research
ARWR
$3.55B
| $78.2K | 0.04% |
3,078
-1,186
| -28% | -$30.1K |
|
|
AMRS
388
DELISTED
Amyris Inc.
AMRS
| $78.2K | 0.04% |
57,485
-22,100
| -28% | -$30.1K |
|
|
NGM
389
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $77.2K | 0.04% |
18,916
-7,265
| -28% | -$29.6K |
|
390
Atea Pharmaceuticals
AVIR
$270M
| $76.9K | 0.04% |
22,948
-8,814
| -28% | -$29.5K |
|
391
Rocket Pharmaceuticals
RCKT
$350M
| $76.1K | 0.04% |
4,441
-1,713
| -28% | -$29.3K |
|
392
Denali Therapeutics
DNLI
$2.26B
| $75.9K | 0.04% |
3,293
-1,259
| -28% | -$29K |
|
393
Atara Biotherapeutics
ATRA
$86.7M
| $75.6K | 0.04% |
26,074
-10,026
| -28% | -$29.1K |
|
394
AbCellera Biologics
ABCL
$1.21B
| $75.3K | 0.04% |
9,983
-3,844
| -28% | -$29K |
|
395
Codexis
CDXS
$227M
| $75.1K | 0.04% |
18,136
-6,966
| -28% | -$28.8K |
|
396
AnaptysBio
ANAB
$577M
| $75K | 0.04% |
3,448
-1,326
| -28% | -$28.9K |
|
397
Recursion Pharmaceuticals
RXRX
$2.02B
| $73.9K | 0.04% |
11,085
-4,257
| -28% | -$28.4K |
|
398
Arvinas
ARVN
$580M
| $73.4K | 0.04% |
2,688
-1,033
| -28% | -$28.2K |
|
399
Nurix Therapeutics
NRIX
$696M
| $72.6K | 0.04% |
8,181
-3,151
| -28% | -$28K |
|
400
Immatics
IMTX
$649M
| $72.2K | 0.04% |
10,470
-4,030
| -28% | -$27.8K |
|